Comparison of Dexmedetomidine and Midazolam for Intra-op Sedation in TIVA in Children Undergoing Inguinal Hernia Repair

To Compare Dexmedetomidine and Midazolam for Intra-op Sedation in TIVA in Children Undergoing Inguinal Hernia Repair

Status

UNKNOWN

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05337085

Enrollment

185

Registered

2022-04-20

Start date

2022-06-30

Completion date

2023-03-20

Last updated

2022-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inguinal Hernia

Brief summary

To compare dexmedetomidine and midazolam for intra-op sedation in TIVA in children undergoing inguinal hernia repair. The results of the study if found significant will guide the anesthetist in appropriate choice and dose of sedative drug with highest efficacy and minimum side effects to avoid post operative adverse effects associated with anesthesia

Interventions

DRUGDexmedetomidine

Inj dexmedetomidine and inj midazolam given to 2 groups of participants and sedative effects of both drugs will be observed during surgery

DRUGMidazolam

Midazolam

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

HEALTH_SERVICES_RESEARCH

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

12 Months to 15 Years

Healthy volunteers

Yes

Inclusion criteria

* Male and female paediatric patients In age range neonates to 15 years * Planned for elective inguinal hernia repair * Patients with uncomplicated hernia With ASA class I or II

Exclusion criteria

* Patients undergoing emergency inguinal repair * Patients with ASA class III,IV,V or VI * Patients present with complicated hernia * Patients with BMI above 40kg/m2 * Patients with any allergy to anesthesia * Patients with coagulopathy * Patients with narcotic/opioid addiction

Design outcomes

Primary

Measure	Time frame
Level of sedation assessed through Ramsay Sedation Scale RSS	6 months

Contacts

Primary ContactAnab Farooqi, MBBS

zaibanaab94@gmail.com03337923232

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026